Jiajia Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiajia Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Guoda Lian
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China
1 shared publication Jianping Wu
Department of Nephrology Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou Guangdong 510120 China
1 shared publication- Jinmao Zou
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China
1 shared publication - Kaihong Huang
Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Linjuan Zeng
Cancer Center of the Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai Guangdong 519000 China
1 shared publication Qijia Duan
School of Medicine South China University of Technology Guangzhou Guangdong 510006 China
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (36) , 21268-21271
Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer
Correction for ‘Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer’ by Jinmao Zou et al. , Nanoscale , 2020, 12 , 4473–4490, https://doi.org/10.1039/C9NR04976B.
- 10 September 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (36) , 21268-21271
Open AccessCorrection: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer
Correction for ‘Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer’ by Jinmao Zou et al. , Nanoscale , 2020, 12 , 4473–4490, https://doi.org/10.1039/C9NR04976B.
Kidney‐Targeted Nanoparticles Loaded with the Natural Antioxidant Rosmarinic Acid for Acute Kidney Injury Treatment
Acute kidney injury (AKI) is a common clinical disease with high morbidity and mortality, and with a lack of effective drugs for treatment. Oxidative stress is very important in the occurrence and progression of AKI, and antioxidants use is one of the promising treatments. Rosmarinic acid (RA) is a ubiquitous natural polyphenol with powerful antioxidant and anti‐inflammatory activities. Due to its inherent characteristic with poor water solubility and inferior bioavailability, its clinical application is impeded. Hence, the authors design a nanoparticle for effectively delivering RA, which is a chemical complex of RA and fourth‐generation poly‐amidoamine‐based amphiphilic polymer (G4‐PAMAM). The nanoparticle is modified with l‐serine due to the specific interaction between kidney injury molecule–1 (Kim‐1) and serine, which eventually generates a promising AKI kidney–targeting nanoparticle (S‐G‐R). The S‐G‐R is rapidly cumulated and long‐term retained in ischemia‐reperfusion–induced AKI kidneys, especially in the damaged renal tubular cells. The S‐G‐R exhibits more excellent antioxidative and antiapoptotic effects in vitro and has a more outstanding ability to improve the renal function, repair damaged renal tissue, and decrease oxidative stress, inflammatory response and apoptosis of tubular cells in vivo. Overall, this study might develop a safe and effective targeting strategy for the therapy of AKI.
Kidney‐Targeted Nanoparticles Loaded with the Natural Antioxidant Rosmarinic Acid for Acute Kidney Injury Treatment
Acute kidney injury (AKI) is a common clinical disease with high morbidity and mortality, and with a lack of effective drugs for treatment. Oxidative stress is very important in the occurrence and progression of AKI, and antioxidants use is one of the promising treatments. Rosmarinic acid (RA) is a ubiquitous natural polyphenol with powerful antioxidant and anti‐inflammatory activities. Due to its inherent characteristic with poor water solubility and inferior bioavailability, its clinical application is impeded. Hence, the authors design a nanoparticle for effectively delivering RA, which is a chemical complex of RA and fourth‐generation poly‐amidoamine‐based amphiphilic polymer (G4‐PAMAM). The nanoparticle is modified with l‐serine due to the specific interaction between kidney injury molecule–1 (Kim‐1) and serine, which eventually generates a promising AKI kidney–targeting nanoparticle (S‐G‐R). The S‐G‐R is rapidly cumulated and long‐term retained in ischemia‐reperfusion–induced AKI kidneys, especially in the damaged renal tubular cells. The S‐G‐R exhibits more excellent antioxidative and antiapoptotic effects in vitro and has a more outstanding ability to improve the renal function, repair damaged renal tissue, and decrease oxidative stress, inflammatory response and apoptosis of tubular cells in vivo. Overall, this study might develop a safe and effective targeting strategy for the therapy of AKI.